Daily Endocrinology Research Analysis
Analyzed 33 papers and selected 3 impactful papers.
Summary
Analyzed 33 papers and selected 3 impactful articles.
Selected Articles
1. Mitochondrial calcium regulates lipid metabolism by modulating tethering of mitochondria to lipid droplets.
In brown adipocytes, elevated mitochondrial matrix Ca2+ triggers detachment of peridroplet mitochondria, facilitating lipolysis. NCLX deletion favored detachment, while its activation promoted attachment; PDE2A inhibition increased peridroplet mitochondria in vitro and in vivo, linking Ca2+ handling to lipid catabolism.
Impact: This work uncovers a previously unrecognized Ca2+-dependent switch controlling mitochondria–lipid droplet contacts and lipolysis, offering a mechanistic basis for metabolic regulation in thermogenic fat.
Clinical Implications: Although preclinical, targeting NCLX/PDE2A-mediated mitochondrial Ca2+ handling could modulate lipid mobilization in obesity and metabolic disease, informing future drug development for thermogenic or lipolytic enhancement.
Key Findings
- Elevated mitochondrial matrix Ca2+ is a potent inducer of mitochondria–lipid droplet detachment, enabling higher lipolytic activity.
- Genetic deletion of NCLX reduced attachment and increased detachment; NCLX activation increased attachment of peridroplet mitochondria.
- PDE2A inhibition activated NCLX signaling and increased peridroplet mitochondria in BAT in vitro and in vivo, linking Ca2+ handling to LD tethering morphology.
Methodological Strengths
- Ex vivo reconstitution of mitochondria–lipid droplet interactions with functional lipase assays.
- Mechanistic triangulation using genetic (NCLX deletion) and pharmacologic (PDE2A inhibition) perturbations in vitro and in vivo.
Limitations
- Findings are limited to brown adipose tissue models; generalizability to white adipose tissue and human physiology is unproven.
- Metabolic outcomes (e.g., whole-body energy expenditure) were not directly assessed in disease models.
Future Directions: Test NCLX/PDE2A modulation in human adipocytes and in vivo metabolic disease models to quantify effects on thermogenesis, lipolysis, and insulin sensitivity.
Adrenergic stimulation of brown adipocytes induces a robust detachment of mitochondria from lipid droplets (LD), which is followed by lipolysis and lipid catabolism. However, the signals inducing mitochondria attachment or detachment, and their role in lipid metabolism, remain unknown. Here, we reconstituted mitochondria-LD interaction in brown adipocyte tissue (BAT) ex vivo. We find that removal of mitochondria from lipid droplets permits higher lipolytic activity of recombinant lipases. Testing the effect of thermog
2. Multi-omics integration identifies macrophage senescence driven by the RUNX1-P53 axis as a key mechanism in diabetic foot ulcer.
Integrating bulk and single-cell RNA-seq, the authors identify senescent macrophages as the dominant stromal senescence population in DFU, with a proinflammatory SASP and aberrant endothelial signaling. A validated macrophage senescence score predicts DFU, and RUNX1 promotes P53 acetylation under diabetic conditions, positioning the RUNX1–P53 axis as a mechanistic driver.
Impact: This study bridges discovery and translation by defining a disease-relevant senescence program, proposing a predictive score, and nominating the RUNX1–P53 axis as a precise therapeutic target in DFU.
Clinical Implications: Macrophage senescence scoring could support DFU risk stratification, and targeting RUNX1–P53 signaling or SASP may improve wound healing through senescence modulation.
Key Findings
- Senescent macrophages are the most prominent stromal senescent cell population in DFU with a pro-inflammatory SASP.
- A macrophage senescence score (MSS), integrating aging GWAS and DFU signatures, predicts DFU and outperforms alternatives.
- RUNX1 is a top regulator; under diabetic conditions RUNX1 associates with increased P53 acetylation, mechanistically driving macrophage senescence and aberrant CXCL8–ACKR1 endothelial signaling.
Methodological Strengths
- Integration of bulk and single-cell transcriptomics with machine learning to derive and validate a disease-relevant score.
- Functional in vitro validation linking RUNX1 to P53 acetylation under diabetic conditions.
Limitations
- Clinical prospective validation of MSS and interventional targeting of RUNX1–P53 were not performed.
- Heterogeneity of publicly sourced datasets may introduce batch effects despite integration strategies.
Future Directions: Prospectively validate MSS in clinical DFU cohorts and test pharmacologic modulation of RUNX1–P53 or SASP in preclinical wound-healing models.
Diabetic foot ulcer (DFU) is a severe complication of diabetes, characterized by chronic inflammation and impaired healing. Although cellular and immunosenescence are associated with chronic wounds, the specific cell types, regulatory mechanisms, and pathological consequences within the DFU microenvironment remain poorly defined. We conducted an integrative multi-omics analysis combining bulk and single-cell RNA sequencing data from human DFU and control tissues. The novel macrophage senescence s
3. Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).
An ENETS-led modified Delphi consensus (34 experts, four rounds) proposes SSTR-PeRForm, a standardized somatostatin receptor PET response framework prioritizing volumetric changes and new lesions over SUV metrics, with categories for PR (≥40% volume reduction), PD (≥40% increase or new lesions), CR (no pathological uptake), and unconfirmed PD.
Impact: Provides the first pragmatic, harmonized SSTR-PET response criteria for NETs, enabling consistent trial endpoints and clinical decision-making across centers.
Clinical Implications: Adopting SSTR-PeRForm can standardize response assessment in NET trials, improve comparability of therapeutic outcomes (e.g., PRRT), and guide short-interval reassessment in equivocal cases.
Key Findings
- Consensus framework defines response primarily by volumetric change of SSTR-expressing lesions with thresholds: PR ≥40% reduction; PD ≥40% increase or new lesions; CR requires absence of pathological uptake.
- Introduces an 'unconfirmed PD' category advocating short-interval reassessment, acknowledging imaging ambiguities.
- SUV-based metrics are de-emphasized in favor of volumetric assessment and lesion emergence for harmonized reporting.
Methodological Strengths
- Structured modified Delphi process with multidisciplinary international experts and predefined consensus thresholds.
- Clear operational definitions to enhance reproducibility and cross-trial comparability.
Limitations
- Framework not yet validated against survival outcomes or prospective clinical datasets.
- Volumetric assessment requires standardization of acquisition/segmentation workflows across centers.
Future Directions: Prospectively validate SSTR-PeRForm against clinical outcomes and integrate with hybrid criteria combining SSTR- and FDG-PET where appropriate.
Somatostatin receptor PET imaging is integral to the management of patients with neuroendocrine tumours (NETs), yet standardised criteria for therapy response assessment with the use of this modality are not available. This Policy Review reports the development of the European Neuroendocrine Tumor Society somatostatin receptor PET response assessment framework, established through a structured modified Delphi process coordinated by the European Neuroendocrine Tumor Society. 34 international exper